Ablation therapies, including Radiofrequency Ablation (RFA) and Microwave Ablation (MWA), are the dominant segments. These techniques are widely adopted due to their ability to destroy malignant tissues accurately while sparing healthy structures. Embolisation therapies, such as TACE and TARE, also hold significant market share, particularly for treating liver cancers.
AI is being integrated into imaging and navigation platforms to enhance procedural precision. For example, Philips Healthcare recently introduced an AI-based platform that enables real-time visualization of tumors and precise catheter placement, which improves safety and treatment outcomes.
The shift toward interventional oncology is driven by the demand for minimally invasive procedures that offer shorter hospital stays, fewer post-operative complications, and a superior quality of life. These procedures are increasingly preferred for patients who are unfit for conventional surgical resection.
North America currently leads the market due to its advanced healthcare infrastructure, high cancer incidence, and favorable reimbursement policies. However, the Asia-Pacific region is expected to be the fastest-growing market, fueled by rapid healthcare modernization and an increasing cancer burden in countries like China, India, and Japan.
The primary barriers include the high cost of imaging equipment and specialized devices, as well as a significant shortage of trained interventional radiologists and oncologists, particularly in low-income and emerging economies.
In 2024, Boston Scientific launched an advanced cryoablative platform for inoperable lung tumors and a new generation of embolic microspheres for liver cancer. Additionally, Siemens Healthineers received approval for a microwave ablation device specifically for hepatic tumors.
Tumor biopsy remains a cornerstone of the market, as it is essential for confirmed diagnosis and the development of personalized treatment plans. Advances in biopsy needles and imaging integration are further improving diagnostic accuracy and safety.
Hybrid procedures combine localized interventional techniques (like ablation or embolisation) with systemic therapies (such as chemotherapy or immunotherapy). These models are gaining traction because they maximize treatment efficacy by targeting tumors directly while minimizing systemic toxicity.
The market is characterized by leading MedTech corporations, including Boston Scientific Corporation, Medtronic plc, Terumo Corporation, Merit Medical Systems, Siemens Healthineers, Johnson & Johnson (Ethicon), BTG International Ltd., AngioDynamics Inc., and Philips Healthcare.
